INM
Price
$3.32
Change
-$0.10 (-2.92%)
Updated
Jun 3 closing price
Capitalization
4.01M
OMER
Price
$3.14
Change
+$0.06 (+1.95%)
Updated
Jun 3 closing price
Capitalization
183.98M
63 days until earnings call
Interact to see
Advertisement

INM vs OMER

Header iconINM vs OMER Comparison
Open Charts INM vs OMERBanner chart's image
InMed Pharmaceuticals
Price$3.32
Change-$0.10 (-2.92%)
Volume$1.24M
Capitalization4.01M
Omeros
Price$3.14
Change+$0.06 (+1.95%)
Volume$721.33K
Capitalization183.98M
INM vs OMER Comparison Chart
Loading...
INM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OMER
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INM vs. OMER commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INM is a Hold and OMER is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (INM: $3.32 vs. OMER: $3.14)
Brand notoriety: INM and OMER are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INM: 67% vs. OMER: 68%
Market capitalization -- INM: $4.01M vs. OMER: $183.98M
INM [@Biotechnology] is valued at $4.01M. OMER’s [@Biotechnology] market capitalization is $183.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $321.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INM’s FA Score shows that 0 FA rating(s) are green whileOMER’s FA Score has 0 green FA rating(s).

  • INM’s FA Score: 0 green, 5 red.
  • OMER’s FA Score: 0 green, 5 red.
According to our system of comparison, both INM and OMER are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INM’s TA Score shows that 8 TA indicator(s) are bullish while OMER’s TA Score has 5 bullish TA indicator(s).

  • INM’s TA Score: 8 bullish, 1 bearish.
  • OMER’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, INM is a better buy in the short-term than OMER.

Price Growth

INM (@Biotechnology) experienced а +19.42% price change this week, while OMER (@Biotechnology) price change was -0.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.76%. For the same industry, the average monthly price growth was +2.77%, and the average quarterly price growth was +0.74%.

Reported Earning Dates

INM is expected to report earnings on May 12, 2025.

OMER is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+5.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OMER($184M) has a higher market cap than INM($4.01M). INM YTD gains are higher at: -27.669 vs. OMER (-68.219). INM has higher annual earnings (EBITDA): -7.44M vs. OMER (-155.96M). OMER has more cash in the bank: 123M vs. INM (3.42M). INM has less debt than OMER: INM (949K) vs OMER (209M). INM has higher revenues than OMER: INM (4.83M) vs OMER (0).
INMOMERINM / OMER
Capitalization4.01M184M2%
EBITDA-7.44M-155.96M5%
Gain YTD-27.669-68.21941%
P/E Ratio0.01N/A-
Revenue4.83M0-
Total Cash3.42M123M3%
Total Debt949K209M0%
FUNDAMENTALS RATINGS
INM vs OMER: Fundamental Ratings
INM
OMER
OUTLOOK RATING
1..100
392
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8997
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INM's Valuation (39) in the null industry is in the same range as OMER (45) in the Biotechnology industry. This means that INM’s stock grew similarly to OMER’s over the last 12 months.

INM's Profit vs Risk Rating (100) in the null industry is in the same range as OMER (100) in the Biotechnology industry. This means that INM’s stock grew similarly to OMER’s over the last 12 months.

INM's SMR Rating (100) in the null industry is in the same range as OMER (100) in the Biotechnology industry. This means that INM’s stock grew similarly to OMER’s over the last 12 months.

INM's Price Growth Rating (89) in the null industry is in the same range as OMER (97) in the Biotechnology industry. This means that INM’s stock grew similarly to OMER’s over the last 12 months.

INM's P/E Growth Rating (100) in the null industry is in the same range as OMER (100) in the Biotechnology industry. This means that INM’s stock grew similarly to OMER’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INMOMER
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 8 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
72%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
INM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OMER
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MRAM5.760.18
+3.23%
Everspin Technologies
GSAT18.950.38
+2.05%
Globalstar Inc
KNSL473.990.86
+0.18%
Kinsale Capital Group
OST5.72N/A
N/A
Ostin Technology Group Co Ltd
SONN1.17N/A
-0.25%
Sonnet BioTherapeutics Holdings Inc

INM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INM has been loosely correlated with TTNP. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INM jumps, then TTNP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INM
1D Price
Change %
INM100%
-2.92%
TTNP - INM
43%
Loosely correlated
-2.25%
EYEN - INM
39%
Loosely correlated
+26.35%
OMER - INM
36%
Loosely correlated
+1.95%
VTYX - INM
31%
Poorly correlated
-2.45%
PULM - INM
30%
Poorly correlated
+1.34%
More

OMER and

Correlation & Price change

A.I.dvisor indicates that over the last year, OMER has been loosely correlated with VCYT. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if OMER jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OMER
1D Price
Change %
OMER100%
+1.95%
VCYT - OMER
40%
Loosely correlated
-0.90%
INM - OMER
36%
Loosely correlated
-2.92%
MDXG - OMER
33%
Loosely correlated
+1.41%
PRME - OMER
32%
Poorly correlated
+11.76%
FULC - OMER
31%
Poorly correlated
+1.08%
More